title: A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
abstract: Under certain instances, factor VIII (FVIII) stimulates an immune response, and the resulting neutralizing antibodies present a significant clinical challenge. Immunotherapies to re-establish or induce long-term tolerance would be beneficial, and an in-depth knowledge of mechanisms involved in tolerance induction is essential to develop immune-modulating strategies. We have developed a murine model system for studying mechanisms involved in induction of immunologic tolerance to FVIII in hemophilia A mice. We used lentiviral vectors to deliver the canine FVIII transgene to neonatal hemophilic mice and demonstrated that induction of long-term FVIII tolerance could be achieved. Hemophilia A mice are capable of mounting a robust immune response to FVIII after neonatal gene transfer, and tolerance induction is dependent on the route of delivery and type of promoter used. High-level expression of FVIII was not required for tolerance induction and, indeed, tolerance developed in some animals without evidence of detectable plasma FVIII. Tolerance to FVIII could be adoptively transferred to naive hemophilia recipient mice, and FVIII-stimulated splenocytes isolated from tolerized mice expressed increased levels of interleukin-10 and decreased levels of interleukin-6 and interferon-gamma. Finally, induction of FVIII tolerance mediated by this protocol is associated with a FVIII-expandable population of CD4(+)CD25(+)Foxp3(+) regulatory T cells.
authors.affiliation: Department of Pathology and Molecular Medicine, Queen's University, Richardson Laboratory, 88 Stuart St., Kingston, Ontario, Canada.
authors.forename: Hideto
authors.initials: H
authors.lastname: Matsui
authors.forename: Masaru
authors.initials: M
authors.lastname: Shibata
authors.forename: Brian
authors.initials: B
authors.lastname: Brown
authors.forename: Andrea
authors.initials: A
authors.lastname: Labelle
authors.forename: Carol
authors.initials: C
authors.lastname: Hegadorn
authors.forename: Chandler
authors.initials: C
authors.lastname: Andrews
authors.forename: Marinee
authors.initials: M
authors.lastname: Chuah
authors.forename: Thierry
authors.initials: T
authors.lastname: VandenDriessche
authors.forename: Carol H
authors.initials: CH
authors.lastname: Miao
authors.forename: Christine
authors.initials: C
authors.lastname: Hough
authors.forename: David
authors.initials: D
authors.lastname: Lillicrap
mesh_terms: D019264:Adoptive Transfer / Q000379:methods*; D000818:Animals; D000831:Animals, Newborn; D016207:Cytokines / Q000096:biosynthesis / Q000187:drug effects; D005169:Factor VIII / Q000008:administration & dosage / Q000276:immunology*; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D006467:Hemophilia A / Q000276:immunology* / Q000628:therapy; D007108:Immune Tolerance; D051379:Mice; D023421:Models, Animal; D013154:Spleen / Q000166:cytology; D013601:T-Lymphocytes / Q000637:transplantation; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D016207:Cytokines; D005169:Factor VIII